Evidence map›Paper›PMID 28689240›Full record

ReviewPflugers Archiv : European journal of physiology2017

suPAR and chronic kidney disease-a podocyte story.

Martin Zeier, Jochen Reiser

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pflugers Archiv : European journal of physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Observational
  7. Article
  8. Review
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. The Perspective of Vitamin D on suPAR-Related AKI in COVID-19.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Article
  19. Review
  20. Nanobodies: new avenue to treat kidney disease.Cell and tissue research · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Martin ZeierDivision of Nephrology, Ruprecht Karls University of Heidelberg, Heidelberg, Germany.
Jochen ReiserDepartment of Medicine, Rush University Medical Center, Kellogg Building, Suite 1003, Chicago, IL, 60612, USA. Jochen_Reiser@rush.edu.ORCID http://orcid.org/0000-0002-0460-662X
Heidelberg University · DERush University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The soluble urokinase-type plasminogen activator receptor (suPAR) is a circulating signaling molecule derived from immature myeloid cells. Elevated levels of suPAR have been linked to the pathogenesis of the kidney disease focal and segmental glomerulosclerosis. Here, suPAR acts on podocytes by activating αvβ3 integrins. Large observational studies showed that suPAR also predicts chronic kidney disease incidence and progression by predating the disease by several years prior to any other known marker of renal dysfunction. suPAR is rapidly developing into a prime target for pharmacotherapy as its neutralization is forecasted to be feasible and safe.

Indexed as

AnimalsBiomarkersGlomerulosclerosis, Focal SegmentalHumansIntegrin alphaVbeta3PodocytesReceptors, Urokinase Plasminogen ActivatorRenal Insufficiency, ChronicBiomarkersIntegrin alphaVbeta3Receptors, Urokinase Plasminogen ActivatorCKDFSGSIntegrinPodocytesuPAR

Identifiers

PMID28689240
OpenAlexW2727569922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.